SOURCE: Equity News Circuit

Equity News Circuit

May 21, 2013 08:20 ET

Free Research Reports on CAMT, DSCO, JRCC and RPTP Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - May 21, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Camtek Ltd. (NASDAQ: CAMT) shares soared 20.83 percent on volume of 1.26 million shares traded Monday to close at $2.03 a share. The company reported GAAP net loss shrunk to $0.9 million, or $0.03 per share, for the first quarter of 2013, from a net loss of $3.3 million, or $0.11 per share in the previous quarter.

Find out more about Camtek including full access to the free equity report at: www.ParagonReport.com/CAMT

Discovery Laboratories, Inc. (NASDAQ: DSCO) shares spiked 12.67 percent on more than three times the average daily volume Monday to close at $1.69 a share. The company has recently completed a $14.25 million public offering. Discovery Laboratories reported a net loss of $12.6 million ($0.29 per share) for the first quarter of 2013.

Find out more about Discovery Laboratories including full access to the free equity report at: www.ParagonReport.com/DSCO

James River Coal Company (NASDAQ: JRCC) shares surged 15.16 percent on volume of 3.20 million shares traded Monday to close at $2.81. The company announced agreements to exchange a total of approximately $243.4 million of existing senior convertible notes for $123.3 million in new debt.

Find out more about James River Coal Company including full access to the free equity report at: www.ParagonReport.com/JRCC

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) shares jumped 11.66 percent on volume of 1.5 million shares traded Monday to close at $6.51. On April 30, 2013, PROCYSBI, a treatment for nephropathic cystinosis, received marketing approval from the U.S. Food and Drug Administration.

Find out more about Raptor Pharmaceutical including full access to the free equity report at: www.ParagonReport.com/RPTP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information